Explore our efforts

Nivalis Therapeutics, Inc.

Nivalis Therapeutics (formerly N30 Pharmaceuticals) is headquartered in Boulder, Colorado. Our company is small, but passionate and growing. We have transitioned from an early-stage company solely focused on preclinical exploration, to a clinical-stage company that is focused on translating bench-side science into patient benefit.

About Us

Leading Innovation in
Cystic Fibrosis

Innovative Engineering in Cystic Fibrosis.

Learn more  

Contact Nivalis

Nivalis Therapeutics, Inc.
3122 Sterling Circle
Boulder, CO 80301
720-945-7700

Contact Us  

Latest News

  • 22
    June
  • June 22, 2015

    Nivalis Therapeutics Announces Closing of Its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on treating people ... More

  • 17
    June
  • June 17, 2015

    Nivalis Therapeutics Announces Pricing of its Initial Public Offering

    Nivalis Therapeutics, Inc., (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, announced today the pricing of its initial public offering of 5.5 million shares of its common stock ... More

  • 13
    May
  • May 13, 2015

    Nivalis Therapeutics, Inc. Announces Filing Registration Statement on Form S-1

    Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for patients with cystic fibrosis, announced today that it has filed a ... More

  • 24
    Feb
  • Feburary 24, 2015

    N30 Pharmaceuticals Announces Name Change to Nivalis Therapeutics

    N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc ... More

  • 3
    Feb
  • N30 Pharmaceuticals Appoints R. Michael Carruthers as Chief Financial Officer

    Boulder, Colo., February 3, 2015 – N30 Pharmaceuticals, Inc. (“N30 Pharma”), a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF) announced today that R. Michael ... More

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.